Background: Acute Myeloid Leukemia (AML) is a particularly heterogeneous malignancy, for which standard care often fails to reach a durable response. Given the high inter-individual diversity, patients could potentially benefit from therapies tailored to an individual’s unique molecular profile, background and physical status. Such efforts are currently pioneered by genomics technologies, yet most therapeutics aim to alter the activity of proteins rather than genes. At the same time, our knowledge about the functi…